Studies brain energy use in young adults with a first episode of psychosis
Observes how antipsychotic medicines affect brain metabolism in young adults with early psychosis.
Plain-language title generated from the registry record
Registry title: The ATP Project (Antipsychotic-TEP-Psychosis)
Key facts
- Where
- Sherbrooke, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 35 years old?
Source: NCT06651112, who can take part
Where in Canada
- Hotel-Dieu CIUSSS de l'Estrie-CHUSSherbrooke, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Université de Sherbrooke
- Trial code
- NCT06651112
- Record updated
- 26 October 2026
- Original description
The goal of this observational study is to the early impacts of psychosis and antipsychotic medications on brain metabolism in young adults recently diagnosed with a first episode of psychosis.Read full original descriptionShow less
Impacts of Psychosis and Antipsychotics on Cerebral Energy Metabolism: the ATP Project (Antipsychotic-TEP-Psychosis)
The goal of this observational study is to the early impacts of psychosis and antipsychotic medications on brain metabolism in young adults recently diagnosed with a first episode of psychosis.
The main question aims to evaluate the effect of 4 to 6 weeks of antipsychotic medication on brain metabolism measured by PET scan (cerebral uptake of 11C-Acetoacetate + 18 Fluorodeoxyglucose).
Participants will undergo a multimodal imaging protocol with other measures of psychopathology (e.g., cognition, depressive symptoms, etc.) and (metabolic marker, inflammation, etc).
Inclusion: Admission to the PEP clinic in Estrie, either outpatient or inpatient, according to the transdiagnostic PEP model; Willingness to begin taking an AP (regardless of type and dose, or change in type and dose during the study); Ability to read and express themselves in French or English; Capable of understanding and signing consent.
Exclusion: The following comorbidities: psychosis + borderline or intellectual disability, autism spectrum disorder, substance use disorder with decompensation, psychosis induced by a medical condition, or psychosis induced by drug use or withdrawal; Type 1 diabetes; Other conditions that could interfere with participation according to the judgment of the qualified physician; Pregnancy, childbirth in the last 6 months, or breastfeeding; Presence of a metallic object in the body that is incompatible with MRI; Any use of APs for more than 2 continuous weeks in the past year and/or 6 weeks in a lifetime (except for aripiprazole if taken at less than 2.5 mg/day or quetiapine at less than 50 mg/day, regardless of duration or timing of the prescription); Uncontrolled acute suicidal ideation.